Therapeutic target discovery using AI & Single Cell technologies

One Biosciences specializes in advanced single-cell technologies aimed at enhancing precision medicine, particularly in the field of oncology. Their proprietary technology leverages AI-driven analysis to create detailed functional profiles of individual tumors, allowing for a deeper understanding of the complex biology associated with advanced cancer. This high-resolution omics profiling is designed to optimize patient selection for clinical trials, inform the development of novel therapies, and improve treatment strategies. Their flagship solutions, OneMap™ and OneCure™, focus on integrating molecular profiling into clinical practice and refining patient population selection for clinical development, respectively.

The company’s innovative approach addresses the challenges of cancer treatment by deconvoluting the intricate biological mechanisms at play within tumors. By utilizing cutting-edge single-cell technologies, One Biosciences aims to facilitate better clinical outcomes through personalized medicine. Their commitment to advancing cancer care is reflected in their collaborations with leading research institutions and their ongoing projects that seek to translate these technologies into practical applications for patient benefit.

France

One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences.

One Biosciences

Company Details